Jump to Main Content
cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer
- Liu, Peifeng, Qin, Liubin, Wang, Qi, Sun, Ying, Zhu, Mingjie, Shen, Ming, Duan, Yourong
- Biomaterials 2012 v.33 no.28 pp. 6739-6747
- antineoplastic agents, breast neoplasms, cytotoxicity, fluorescence, image analysis, lysine, nanoparticles, polyethylene glycol, therapeutics
- Cyclic peptide (arginine-glycine-aspartic-glutamic-valine acid, cRGD)-modified monomethoxy (polyethylene glycol)-poly (d,l-lactide-co-glycolide)-poly (l-lysine) nanoparticles (mPEG-PLGA-PLL-cRGD NPs) with antitumor drug Mitoxantrone (DHAQ) or fluorescence agent Rhodamine B (Rb) encapsulated in their interior were prepared. The remarkable features of the mPEG-PLGA-PLL-cRGD NPs are the effective improvement for the cytotoxicity and uptake of the cell in vitro, and the significant enhancement of delivery ability for DHAQ or Rb in vivo. As a consequence, an excellent therapeutic efficiency for cancer is obtained, demonstrating the mPEG-PLGA-PLL-cRGD NPs play a key role in enhancing cancer therapeutic efficiency.